

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM556294

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	MERGER AND CHANGE OF NAME		
EFFECTIVE DATE:	12/31/2018		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
AstraZeneca LP		12/20/2018	Limited Partnership: DELAWARE
NEWLY MERGED ENTITY DATA			
Name	Execution Date	Entity Type	
AstraZeneca Pharmaceuticals LP	12/20/2018	Limited Partnership: DELAWARE	
MERGED ENTITY'S NEW NAME (RECEIVING PARTY)			
Name:	AstraZeneca Pharmaceuticals LP		
Street Address:	1800 Concord Pike		
City:	Wilmington		
State/Country:	DELAWARE		
Postal Code:	19850-5437		
Entity Type:	Limited Partnership: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	0691568	CITANEST	
Registration Number:	2102441	TOPROL-XL	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	3028866934		
Email:	trademarks@astrazeneca.com		
Correspondent Name:	Wm. Charles Saunders		
Address Line 1:	1800 Concord Pike		
Address Line 2:	A2C		
Address Line 4:	Wilmington, DELAWARE 19850-5437		
NAME OF SUBMITTER:	Wm. Charles Saunders		

CH \$65.00 0691568

SIGNATURE:	/wcs/
DATE SIGNED:	01/07/2020
Total Attachments: 5 source=Certificate of Merger_AstraZeneca LP merged with and into AstraZeneca Pharmaceuticals LP#page1.tif source=Certificate of Merger_AstraZeneca LP merged with and into AstraZeneca Pharmaceuticals LP#page2.tif source=Certificate of Merger_AstraZeneca LP merged with and into AstraZeneca Pharmaceuticals LP#page3.tif source=Certificate of Merger_AstraZeneca LP merged with and into AstraZeneca Pharmaceuticals LP#page4.tif source=Certificate of Merger_AstraZeneca LP merged with and into AstraZeneca Pharmaceuticals LP#page5.tif	

Apostille

(Convention de La Haye du 5 Octobre 1961)

1. Country: United States of America

This public document:

2. has been signed by Jeffrey W. Bullock

3. acting in the capacity of Secretary Of State Of Delaware

4. bears the seal/stamp of Office Of Secretary Of State

Certified


5. at Dover, Delaware

6. twenty-third day of October, A.D. 2019

7. by Secretary of State, Delaware Department of State

8. No. 203848302

9. Seal/Stamp:



10. Signature:


Jeffrey W. Bullock, Secretary of State

Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"ASTRAZENECA LP", A DELAWARE LIMITED PARTNERSHIP,
WITH AND INTO "ASTRAZENECA PHARMACEUTICALS LP" UNDER THE NAME OF "ASTRAZENECA PHARMACEUTICALS LP", A LIMITED PARTNERSHIP ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE ON THE TWENTIETH DAY OF DECEMBER, A.D. 2018, AT 12:01 O'CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF MERGER IS THE THIRTY-FIRST DAY OF DECEMBER, A.D. 2018 AT 11:59 O'CLOCK P.M.




Jeffrey W. Bullock, Secretary of State

2810992 8100M
SR# 20197683207

You may verify this certificate online at www.delaware.gov

Authentication: 203848301
Date: 10-23-19

TRADEMARK
REEL: 006832 FRAME: 0525

CERTIFICATE OF MERGER

MERGING

ASTRAZENECA LP

WITH AND INTO

ASTRAZENECA PHARMACEUTICALS LP

The undersigned limited partnership, formed and existing under and by virtue of the Delaware Revised Uniform Limited Partnership Act (the "Act"), does hereby certify that:

FIRST: The name, jurisdiction of formation or organization and type of entity of each of the constituent entities in the merger are as follows:

<u>Name</u>	<u>Jurisdiction of Formation or Organization</u>	<u>Type of Entity</u>
AstraZeneca LP	Delaware	Limited Partnership
AstraZeneca Pharmaceuticals LP	Delaware	Limited Partnership

SECOND: An Agreement and Plan of Merger among the parties to the merger has been approved and executed by each of the constituent entities in accordance with the requirements of Section 17-211 of the Act.

THIRD: The name of the surviving limited partnership is AstraZeneca Pharmaceuticals LP (the "Surviving Entity").

FOURTH: The merger shall be effective on December 31, 2018 at 11:59 p.m. (Eastern time).

FIFTH: The executed Agreement and Plan of Merger is on file at a place of business of the Surviving Entity. The address of the principal place of business of the Surviving Entity is 1800 Concord Pike, Wilmington, Delaware 19850-5437.

SIXTH: A copy of the Agreement and Plan of Merger will be furnished by the Surviving Entity, on request and without cost, to any partner of, or any other person holding an interest in, any of the constituent entities in the merger.

[Signature page follows]

IN WITNESS WHEREOF, AstraZeneca Pharmaceuticals LP has caused this
Certificate of Merger to be duly executed this 20 day of December, 2018.

ASTRAZENECA PHARMACEUTICALS LP

By: AstraZeneca AB, its general partner

By: *Yvonne Bertin*

Name: Yvonne Bertin

Title: Director

12425643.1